

Isolation of Bacteriocin-producing *Staphylococcus* spp. Strains from Human Skin Wounds, Soft Tissue Infections and Bovine Mastitis

MAGDALENA ZALEWSKA^{1,3}, JOHN J. CHUREY², RANDY W. WOROBO³, SŁAWOMIR MILEWSKI¹, PIOTR SZWEDA^{1*}

¹Gdansk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Gdansk, Poland

²Cornell University, Department of Food Science, New York State Agricultural Experiment Station, Geneva, USA

³Cornell University, Department of Food Science, Ithaca, USA

Submitted 08 August 2017, revised 23 October 2017, accepted 20 November 2017

Abstract

A collection of 206 *Staphylococcus* spp. isolates was investigated for their ability to produce compounds exhibiting antistaphylococcal activity. This group included *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus xylosus* strains recovered from bovine mastitis (n = 158) and human skin wounds and soft tissues infections (n = 48). Production of substances with antimicrobial activity was observed in six strains. Five of them were recovered from bovine mastitis, and one was isolated from the infected human skin wound. Three of the six antimicrobials produced by the different strains showed substantial loss of antimicrobial activity upon treatment with proteolytic enzymes, which suggests their peptidic structure. Additional studies have shown that one of the putative bacteriocins was efficiently secreted to the liquid medium, facilitating its large-scale production and isolation. The peptide produced by the M2B strain exhibited promising activity; however, against narrow spectrum of *Staphylococcus* spp. clinical and animal isolates. Growth inhibition was observed only in the case of 13 (including nine *S. aureus*, three *S. xylosus* and one *S. epidermidis* strains) out of 206 strains tested. Important advantage of the produced agent was its high thermal stability. Fifteen minutes of incubation at 90°C did not affect its antimicrobial potential. The highest efficiency of production of the agent was demonstrated in TSB medium after 24 hours at 37°C. The researches revealed that ability to production of bacteriocin among staphylococci is not very common. Only one (*S. xylosus* strain assigned as M2B) out of 206 strains tested produced satisfactory amounts of antistaphylococcal bacteriocin. In spite of that, we would encourage other researchers for investigation of their collections of *Staphylococcus* spp. isolates towards selection strains producing antimicrobial agents.

Key words: antimicrobial peptides, antistaphylococcal agents, *Staphylococcus*, *Staphylococcus aureus*, *Staphylococcus xylosus*

Introduction

Bacterial cells may produce several types of substances that inhibit the growth of other microorganisms. These antimicrobial agents belong to different classes of molecules, ranging from the simple compounds, like hydrogen peroxide or lactic acid to more complicated: antibiotics, peptides, exotoxins or lytic enzymes (Brito *et al.*, 2011). Among them, the agents of proteinaceous nature, peptides and proteins, seem to be especially interesting. Bacteria produce two essential classes of products of this type: bacteriocins and peptide antibiotics. Both of them are secreted to help the host strain to eliminate other microorganisms from the place of its growth. However, there are some important differences between these two classes of agents. First of

all, enzymes synthesize the peptide antibiotics, whilst the bacteriocins are ribosomally synthesized. Bacteriocins are targeted at a narrow spectrum of bacteria often within the species of the producer or closely related ones, while the classical antibiotics are active against broad spectra of bacteria. Another important feature that separates bacteriocins from antibiotics is their potency against susceptible bacteria; bacteriocins are unique because they can kill bacteria at nanomolar concentrations, while antibiotics are needed in much higher concentrations (Nes, 2011). The bacteriocins are included in the larger group of antimicrobial substances defined as antimicrobial peptides (AMPs). These peptides are ribosomally synthesized by all domains of living organisms (eukaryotes, bacteria and archaea). Similarly as bacteria the other organisms (*e.g.* plants,

* Corresponding author: P. Szweda, Gdansk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Gdansk, Poland; e-mail: piotr.szweda@wp.pl

animals and humans) produce AMPs for elimination of pathogenic microorganisms and prevention of infections (AMPs constitute an important element of their innate immune system) (Rashid *et al.*, 2016). AMPs such as human defensins, human neutrophil peptides and many bacterial bacteriocins are cationic and are able to bind to anionic parts of bacterial surface (*e.g.* anionic lipids or other anionic components) (Joerger, 2003). AMPs could undergo posttranslational modification *e.g.* proteolytic processing or glycosylation (Rashid *et al.*, 2016).

The modes of action of AMPs, including most of the bacteriocins, involve interactions with the bacterial cell membrane, and forming complexes with lipid II – a highly conserved precursor of the bacterial cell wall (Malanovic and Lohner, 2016). Cell membrane permeabilization leads to efflux of important intracellular molecules such as mono- and divalent ions (K^+ , Na^+ , Ca^{2+} and Mg^{2+}) and ATP (Di Meo *et al.*, 2016; Yeaman and Yount, 2003). Binding the peptides with lipid II inhibits peptidoglycan synthesis and additionally promotes pore formation and membrane disruption (Malanovic and Lohner, 2016). Structure-activity analyses of a broad range of peptides showed two main requirements for their antimicrobial activity: (1) a cationic charge and (2) an induced amphipathic conformation. The diversity of lipids among pathogens could explain the differences in activity of a single peptide between different types of microorganisms (Powers and Hancock, 2003).

Due to high selectivity and activity against a substantial array of pathogenic microorganisms, AMPs are a promising alternative to conventional antibacterial antibiotics (Kosikowska and Lesner, 2016; Ołdak and Zielińska, 2017). Compared to conventional antibiotic therapy, killing of microorganisms by peptides is more rapid and they can 'attack' multiple molecular targets related to membrane and cell wall, which highly prevents development of resistant strains. However, the results of recent years revealed that many important Gram-positive as well as Gram-negative bacteria, including dangerous human and animal pathogens, have developed mechanisms of modification of most important molecular targets of AMPs, namely cell membrane and lipid II. As a consequence these strains are highly resistant to AMPs' activity (Andersson *et al.*, 2016).

In the present study, a collection of *Staphylococcus* spp. strains isolated from human skin wounds, soft tissues infections, as well as from milk of bovine suffering from mastitis (*S. aureus*, *S. epidermidis*, *S. xylosum*) was screened for their ability to produce antibacterials, particularly with proteinaceous structure, with activity against other staphylococci. This research was focused on identification and preliminary characterization of the newly discovered antimicrobial peptides in order to uncover their potential therapeutic application in

medicine and veterinary science for elimination of pathogenic bacteria from food products and also possibilities of their large-scale production.

Experimental

Materials and methods

Bacterial strains. *Staphylococcus* spp. strains (n=206) were isolated from milk of bovine suffering from mastitis (n=158) (Jakubczak *et al.*, 2007; Kot *et al.*, 2012) and from human skin wounds and soft tissue infections (n=48). Eighteen of the human derived isolates (collected in 2013) were supplied by the Microbial Laboratory at the Provincial Hospital, Koszalin (Poland) and thirty strains were obtained from the Department of Clinical Microbiology, Central Hospital, Växjö (Sweden, collected between November 2006 and April 2007) (Sjölund and Kahlmeter, 2008). All isolates of human origin were classified as *S. aureus* (n=48) and strains isolated from milk belonged to three species: *S. aureus* (n=120), *S. epidermidis* (n=16) and *S. xylosum* (n=22). The strains isolated from mastitis were collected in two periods of time: between January 2005 and December 2006 (90 isolates of *S. aureus*) and between February 2009 and March 2010 (all *S. epidermidis* and *S. xylosum* and remaining *S. aureus*). Additionally *Listeria monocytogenes* and *Micrococcus luteus* strains were used as indicator strains in antimicrobial activity assays. All strains were grown in liquid Tryptic Soy Broth – TSB (Fluka) and on solid Tryptic Soy Agar – TSA (Tryptic Soy Broth + 1.5% agar (Sigma)). The strains were stored at $-70^{\circ}C$ as a cell suspension in PBS buffer (Phosphate Buffered Saline, pH 7.4; Sigma) containing 40% glycerol (vol/vol).

Detection of AMP production. Production of antimicrobial substances by staphylococcal cells was evaluated by the overlay method (Barefoot and Klaenhammer, 1983; Fleming *et al.*, 1975). The single colony (obtained by streaking on TSA agar plates) of the producing strains was transferred with a sterile needle or toothpick on fresh TSA agar plates. After 24 hours of incubation at $37^{\circ}C$, the plates with a single, centrally located, colony – spot of potential producer strains were overlaid with soft TSA medium (Tryptic Soy Broth supplemented with 0.75% Agar) inoculated with cells of the sensitive (indicator) strain to a final concentration of 0.01% (vol/vol). Volume of the soft agar depended on the size of the plate, where soft agar should completely cover the surface of the bottom TSA medium and the producer strain colony. The indicator strains (n=7) included six staphylococci strains isolated from animal infections (1 – *S. xylosum*, 1 – *S. epidermidis* and 4 – *S. aureus*) and one strain of *Listeria monocytogenes* ATCC10425

Table I
The indicator strains used for preliminary selections of staphylococci producing antibacterial agents.

Strain	Source of the strain	Resistance
1 <i>S. xylosus</i> 30c1	Bovine mastitis	ND
2 <i>S. epidermidis</i> 267	Bovine mastitis	ND
3 <i>S. aureus</i> K10	Human skin wound (Koszalin)	Susceptible
4 <i>S. aureus</i> 11	Bovine mastitis	P, AMP, AML, S, AMC*
5 <i>S. aureus</i> 27	Bovine mastitis	N, MY, S, E, DA*
6 <i>S. aureus</i> 101 (MRSA)	Bovine mastitis	P+DA+E+MY+S+N/OX*
7 <i>L. monocytogenes</i> ATCC10425	Reference strain	ND

* – Resistance according to Szweda *et al.* 2014

(Table I). After inoculation, the plates were incubated at 37°C for another 24 h, and the growth inhibition of the indicator cells was determined. The presence of a clear zone around the producer strain colony confirmed production of an active antimicrobial agent. The diameter of the growth inhibitory zone was measured.

Antibacterial activity of the after-culture liquid medium was measured by the agar-well diffusion method (Schillinger and Lücke, 1989). The strains found as producers of antimicrobial agents on TSA agar plates (n=6) were grown in TSB for 24 hours at 37°C. The obtained cell suspensions were centrifuged (14 000 rpm, 10 min, room temperature) to collect the bacterial cells. The collected and filter sterilized (0.22 µm) supernatants (300 µl) were aliquoted into wells (diameter 7 mm) in solid TSA medium (TSB medium supplemented with 1.5% agar). The plates were dried in a laminar flow cabinet, and when the supernatant evaporated completely from the wells, the plates were overlaid with a soft agar layer inoculated with the cells of indicator strains to a final concentration of 0.01% (vol/vol). After incubation (24 h, 37°C), the diameters of clear zones were measured.

Identification of the antimicrobials with proteinaceous nature. The overlay method (described above, section – Detection of AMP production) was also used for identification of proteinaceous nature of antimicrobials produced by the selected strains. The 2 µl of solution of proteolytic enzymes (Pronase E (20 mg/ml), α-Chymotrypsin (25 mg/ml) and Proteinase K (20 mg/ml) (Lee *et al.*, 2008)) were loaded on the surface of the bottom agar medium close to the growing colony of the producing strain – on the suspected border line of inhibition growth zone of indicator strain. The prediction of the diameter of the growth inhibition zone was based on diameters of inhibition area from the results of previous analyses. The changing of the shape of growth inhibition zone – formation of so-called “half moon zone” near the colony of producing strain confirmed susceptibility of the produced agent to the proteolytic enzymes and that the secreted product had the proteinaceous nature.

Determination of the activity spectrum of the identified AMPs. Determination of the potential antimicrobial peptide activity spectrum was performed by the overlay method (as used in the previous tests, section – Detection of AMP production) for the producer strains, which showed protease sensitivity (n=3). All of the isolates from the collection of Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology (n=206) were used to define their susceptibility to the potential antimicrobial peptide. The most sensitive strain (n=1) was selected for investigation of the antimicrobial activity in further tests, *e.g.* the optimization of production or determination of thermostability.

Optimization of AMP production parameters. The conditions for the most effective production of the bacteriocins by the strains selected in the screening procedure were optimized in terms of: (1) medium type (Tryptic Soy Broth (TSB; DB Bioscience), Mueller Hinton Broth (MHB; DB Bioscience), Brain Heart Infusion (BHI; DB Bioscience), Casamino acids (CAA; DB Bioscience) and Luria-Bertani (LB; BD Bioscience); (2) temperature (30°C, 35°C, 37°C), and (3) the growth period (12 h, 24 h and 48 h, 72 h). The cells were grown in suspension cultures with shaking (200 rpm). Samples of the cell suspensions were collected at time intervals (0 h, 3 h, 6 h, 9 h, 12 h, 24 h, 48 h, 72 h), centrifuged (10 000 rpm, 10 min, 4°C) and the activity of the supernatants obtained was determined by the well – overlay method. The first step of the procedure was performed for all (n=3) producer strains, which exhibited sensitivity to proteolytic enzymes (*S. xylosus* M2B, *S. epidermidis* 30c1 and *S. aureus* K1). After that step, we found out that only one antimicrobial peptide, produced by strain named M2B (*S. xylosus*), was efficiently secreted to liquid medium. Thus, other tests were performed only for this strain.

Determination of thermostability. Sample of the supernatant collected from the cultures after 24 h of antimicrobial-producing strain were incubated at 25°C, 50°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C for different

time periods (5 min, 10 min, 15 min, 30 min) and their activity was determined by the well-overlay method.

Identification of the strain. Identification of the producing strain M2B was carried out by sequencing of 16S rRNA gene. PCR amplification of the target gene was carried out with a pair of primers:

rP1 5' CCCGGGATCCAAGCTTAGAGTTTGATC-CTGGCTCAG 3'

fD2 5' CCGAATTCGTCGACAACACGGCTACCTTGTTACGACTT 3'

following the method described by the group of Weisburg (1991). Sequencing of the amplified product was carried out by Macrogen (The Netherlands). The analysis of sequence was performed with using MEGA 6.1 (Molecular Evolutionary Genetics Analysis) software.

Results

Screening of the 206 bacterial isolates resulted in the identification of six strains producing antistaphylococcal agents. Three producing strains were *S. aureus* isolated from bovine mastitis (assigned in the collection as 30, 31 and 32), one was *S. aureus* recovered from human skin wound (K1), one agent was produced by *S. xylosus* M2B and the last of producing strain was *S. epidermidis* 30c1. The antibacterial activity of three (produced by *S. aureus* 30, 31 and 32) out of six substances was not affected by the treatment with proteolytic enzymes, suggesting their non-proteinaceous structure. Further tests eliminated two additional strains (K1 and 30c1), since they produced antimicrobial substances exclusively when grown on solid (agar) medium while no antibacterial activity was detected in the supernatants collected from the suspension cultures. Therefore, completion of the screening procedure resulted in the identification of one strain effectively producing the antibacterial substance with protease-sensitive structure, i.e. potential bacteriocin or peptide antibiotic. This strain (M2B) and the produced agent were the subjects of further analysis.

Based on the sequence of the gene coding for 16S rRNA, the producing strain was identified as *S. xylosus* (99,9% of identity of this gene sequence with the sequences of 16S rRNA genes of other bacteria of the this genus) – labeled in the collection as M2B. The antimicrobial agent synthesized by this strain was efficiently produced both on solid as well as in a liquid medium (Fig. 1a and Fig. 2) and its' activity was eliminated in the presence of proteases (Fig. 3).

The antimicrobial spectrum of the putative antimicrobial peptide produced by *S. xylosus* M2B was determined by the well overlay method. Growth inhibition zones were observed with 13 strains of staphylococci (including nine *S. aureus*, three *S. xylosus* and one

S. epidermidis strains), *L. monocytogenes* and *M. luteus* (Table II). Diameters of the growth inhibitory zones were in the range of 12–25 mm; surprisingly apparent substantial differences in sensitivity to the putative AMPs were found among the different *S. aureus* strains.

Conditions for the effective production of the putative bacteriocin by *S. xylosus* M2B in a liquid culture were optimized in the terms of medium type, time period and incubation temperature. Comparison of



Fig. 1. Growth inhibition zone around the colony of producer strain M2B; an indicator strain – *S. aureus* 30C1.




Fig. 2. Formation of "half moon zone" near the colony of producer strain M2B in the presence of proteolytic enzyme; an indicator strain – *L. monocytogenes*.




Fig. 3. Antimicrobial activity of the after-culture liquid media after growth of the producer strain.

the production efficiency in five different commercially available media, recommended for staphylococci culture, revealed that the optimal production of the putative AMP was observed in TSB medium. Slightly lower level of peptide production was found in MHB and LB media and no production was detected in CAA and BHI media (Fig. 2).

The maximum level of AMP production by *S. xylo-sus* M2B was observed after 24 h of incubation in TSB medium, and the optimal temperature was 37°C.

Table II
Activity of newly identified agent against strains from the Departments' collection.

No. of strain	Code number of the sensitive strain	Growth inhibition zone [mm]
1	7 (<i>S. aureus</i>)	12
2	11 (<i>S. aureus</i>)	20
3	28 (<i>S. aureus</i>)	15
4	52 (<i>S. aureus</i>)	22
5	68 (<i>S. aureus</i>)	25
6	77 (<i>S. aureus</i>)	18
7	92 (<i>S. aureus</i>)	17
8	99 (<i>S. aureus</i>)	25
9	115 (<i>S. aureus</i>)	15
10	83A (<i>S. epidermidis</i>)	15
11	8J (<i>S. xylo-sus</i>)	15
12	30C1 (<i>S. xylo-sus</i>)	15
13	247 (<i>S. xylo-sus</i>)	15
14	<i>L. monocytogenes</i>	15
15	<i>M. luteus</i>	15

The tests of thermostability revealed that the putative antimicrobial peptide did not lose its activity after 15 minutes of heating at 90°C. After 30 min of incubation in 90°C peptide lost its activity (inhibition zone was significantly smaller).

Discussion

Studies on the antimicrobial substances produced by staphylococci, have not been very extensive so far. However, there are a few peptides exhibiting antistaphylococcal activity produced by bacteria that belong to this genus, including both CNS – coagulase negative and CPS – coagulase positive staphylococci. The most promising examples of AMPs produced by CNS are the following bacteriocins: Pep5, epicidin 280, epilancin K7, epidermin, nukacin ISK-1, simulancin 3299, and the most extensively characterized bacteriocins produced by CPS are: staphylococcin C55, aureocin A70, aureocin A53 (Nascimento *et al.*, 2006; Varella Coelho *et al.*, 2007). The detailed characteristics of the best characterized staphylococcins has been presented in the review by Bastos and coworkers (Bastos *et al.*, 2009). The authors also emphasized that staphylococcins may be applied, solely or in a combination with other chemical agents. The use of combinations of antimicrobials is common in the clinical setting, and the most important advantages coming from such approach are: 1) expanding the spectrum of organisms that can be targeted, 2) prevention of the emergence of resistant organisms, 3) decreasing of toxicity by allowing lower doses of both agents (Kurlenda and Grinholc, 2012).

Our studies, results of which are presented in this work, are probably one of the very few examples of an extensive screening aimed at the identification of antimicrobial peptides produced by staphylococci isolated from humans (skin and soft tissue infections $n = 48$) or animals (strains isolated from bovine with mastitis $n = 158$). From the set of 206 strains, we identified six strains producing any antimicrobials (2.9%), of which, one was confirmed to be a putative peptide or protein with antimicrobial activity, efficiently produced in a liquid medium. Two out of three antimicrobial – producing strains identified in these studies did not produce the antimicrobial agents at the detectable level when grown in liquid media. Similar problems were recently observed by Braem and coworkers (2014), who identified *Staphylococcus chromogenes* L217 strain (isolated from teat apices of dairy cows) producing nukacin-like bacteriocin displaying a broad spectrum of antimicrobial activity. Unfortunately, the bacteriocin was only produced in significant quantities when the producer strain was grown on solid agar medium.

The molecular structure of the putative AMP produced by *S. xyloso* M2B is not known until now. This work is in progress in our laboratory, but preliminary results indicate that it could be a novel, previously undescribed compound. Its antimicrobial spectrum is interesting, since it is relatively narrow. Additionally, the good thermostability is advantageous, which could be especially important in the case of potential application of the identified antimicrobial peptide for the elimination of staphylococci from food products, but also for purification procedure, e.g. preliminary separation of the peptide from other components of the cell free after-culture supernatant by the heat treatment.

The produced peptide exhibits also strong activity against other important foodborne pathogenic bacteria *L. monocytogenes*. Thus, it could be also applied for protection of food products against these bacteria.

The recent studies carried out by Hewelt-Belka and coworkers (2016) revealed some important differences in the lipid composition of *S. aureus* clinical isolates. The observed, by the mentioned authors, differences in the lipid patterns between sensitive and resistant *S. aureus* strains suggest that antibiotic susceptibility may be associated with the lipid composition of bacterial cells. The lipids that were found to significantly differ between antibiotic-resistant and antibiotic-sensitive clinical isolates are involved in the biosynthesis of major *S. aureus* membrane lipids and lipoteichoic acid. The research of Powers and Hancock (2003) revealed that the lipid composition of the bacterial cell membrane is crucial for AMPs activity. Thus the observed in our studies differences in the susceptibility of *Staphylococcus* spp. strains tested to the agent produced by M2B can be caused by some differences in the lipid composition of their cell membranes.

In our studies, the prevalence of isolation of strains producing AMPs was found to be at a relatively low level – below 2% (three out of 206 isolates), and only one strain (prevalence below 0.5%) produced a peptide that is worthy of further studies. However, we do not have any doubts that staphylococci represents an interesting and promising source of uncharacterized antimicrobial peptides, which could be used for treatment or prophylaxis of infections caused by other bacteria that belong to the *Staphylococcus* spp. but also other important pathogenic microorganisms e.g. *L. monocytogenes*. Unfortunately, the research in this field is limited. Each year, numerous publications concerning the antibiotic resistance of the staphylococci isolated from both, human and animal (especially bovine mastitis) infections from different world regions are presented. In the case of some of these publications, large populations, counting even several hundreds of isolates, are investigated. Unfortunately, very few of these isolates are investigated for their potential production of anti-

microbial agents. The methods used for screening the 'producing strains' are relatively easy and could be performed in most of microbiological laboratories. Thus, we encourage other research groups, which have access to the large number of human or animal isolates of staphylococci, for investigation of the production ability of potential antimicrobial peptides by these strains.

Funding

The author received funding for the preparation of the doctoral dissertation from the National Science Center in the framework of a doctoral scholarship funding based on the decision number DEC-2014/12/T/NZ9/00534.

The research was also funded by the National Science Center (Grant no. UMO-2012/07/N/NZ9/00939).

Literature

- Andersson D.I., D. Hughes and J.Z. Kubicek-Sutherland. 2016. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. *Drug Resist. Updat.* 26: 43–57.
- Barefoot S.F. and T.R. Klaenhammer. 1983. Detection and activity of lactacin B, a bacteriocin produced by *Lactobacillus acidophilus*. *Appl. Environ. Microbiol.* 45: 1808–1815.
- Bastos M.C.F., H. Ceotto, M.L.V. Coelho and J.S. Nascimento. 2009. *Staphylococcal* antimicrobial peptides: relevant properties and potential biotechnological applications. *Curr. Pharm. Biotechnol.* 10: 38–61.
- Braem G., B. Stijlemans, W. Van Haken, S. De Vliegher, L. De Vuyst and F. Leroy. 2014. Antibacterial activities of coagulase-negative staphylococci from bovine teat apex skin and their inhibitory effect on mastitis-related pathogens. *J. Appl. Microbiol.* 116: 1084–1093.
- Brito M.A.V.P., G.A. Somkuti and J.A. Renye. 2011. Production of antilisterial bacteriocins by staphylococci isolated from bovine milk1. *J. Dairy Sci.* 94: 1194–1200.
- Di Meo F., G. Fabre, K. Berka, T. Ossman, B. Chantemargue, M. Palonciová, P. Marquet, M. Otyepka and P. Trouillas. 2016. In silico pharmacology: Drug membrane partitioning and crossing. *Pharmacol. Res.* 111: 471–486.
- Fleming H.P., J.L. EtcHELLS and R.N. Costilow. 1975. Microbial inhibition by an isolate of *Pediococcus* from Cucumber Brines 1. *Appl. Microbiol.* 30: 1040–1042.
- Hewelt-Belka W., J. Nakonieczna, M. Belka, T. Bączek, J. Namieśnik and A. Kot-Wasik. 2016. Untargeted lipidomics reveals differences in the lipid pattern among clinical isolates of *Staphylococcus aureus* resistant and sensitive to antibiotics. *J. Proteome Res.* 4: 914–22.
- Jakubczak A., P. Szweda, K. Łukaszewska and J. Kur. 2007. Molecular typing of *Staphylococcus aureus* isolated from cows with mastitis in the east of Poland on the basis of polymorphism of genes coding protein A and coagulase. *Pol. J. Vet. Sci.* 10: 199–205.
- Joerger R.D. 2003. Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. *Poultry Sci.* 82: 640–647.
- Kosikowska P. and A. Lesner. 2016. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). *Expert Opin. Ther. Pat.* 26: 689–702.
- Kot B., M. Piechota, M. Antos-Bielska, E. Zdunek, K.M. Wolska, T. Binek, J. Olszewska, P. Guliński and E.A. Trafny. 2012. Antimicrobial resistance and genotypes of staphylococci from bovine milk and the cowshed environment. *Pol. J. Vet. Sci.* 15: 741–749.

- Kurlenda J. and M. Grinholc.** 2012. Alternative therapies in *Staphylococcus aureus* diseases. *Acta Biochim. Pol.* 59: 171–184.
- Lee H., J. Churey and R. Worobo.** 2008. Antimicrobial activity of bacterial isolates from different floral sources of honey. *Int. J. Food Microbiol.* 126: 240–244.
- Malanovic N. and K. Lohner.** 2016. Antimicrobial peptides targeting Gram-positive bacteria. *Pharmaceuticals (Basel)*. 9(3). pii: E59. doi: 10.3390/ph9030059.
- Nascimento J.S., H. Ceotto, S.B. Nascimento, M. Giambiagi-Demarval, K.N. Santos and M.C.F. Bastos.** 2006. Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. *Lett. Appl. Microbiol.* 42: 215–221.
- Nes I.F.** 2011. History, Current Knowledge, and Future Directions on Bacteriocin Research in Lactic Acid Bacteria. In: Drider D. and S. Rebuffat (eds). *Prokaryotic Antimicrobial Peptides*. Springer, New York, NY
- Ołdak A. and D. Zielińska.** 2017. Bacteriocins from lactic acid bacteria as an alternative to antibiotics. *Post. Hig. Med. Dosw.* 71: 328–338.
- Powers J.-P.S. and R.E. Hancock.** 2003. The relationship between peptide structure and antibacterial activity. *Peptides* 24: 1681–1691.
- Rashid R., M. Veleba and K.A. Kline.** 2016. Focal targeting of the bacterial envelope by antimicrobial peptides. *Front. Cell Dev. Biol.* 4:55. doi: 10.3389/fcell.2016.00055.
- Schillinger U. and F.K. Lücke.** 1989. Antibacterial activity of *Lactobacillus sake* isolated from meat. *Appl. Environ. Microbiol.* 55: 1901–1906.
- Sjölund M. and G. Kahlmeter.** 2008. Staphylococci in primary skin and soft tissue infections in a Swedish county. *Scand. J. Inf. Dis.* 40: 894–898.
- Szweda P., M. Schielmann, A. Frankowska, B. Kot and M. Zalewska.** 2014. Antibiotic resistance in *Staphylococcus aureus* strains isolated from cows with mastitis in eastern Poland and analysis of susceptibility of resistant strains to alternative nonantibiotic agents: lysostaphin, nisin and polymyxin B. *J. Vet. Med. Sci.* 76: 355–362.
- Varella Coelho M.L., J.D. Santos Nascimento, P.C. Fagundes, D.J. Madureira, S.S Oliveira, M.A. Vasconcelos de Paiva Brito and C. Freire Bastos Mdo.** 2007. Activity of staphylococcal bacteriocins against *Staphylococcus aureus* and *Streptococcus agalactiae* involved in bovine mastitis. *Res. Microbiol.* 158: 625–630.
- Weisburg W.G., S.M. Barns, D.A. Pelletier and D.J. Lane.** 1991. 16S ribosomal DNA ampigication for phylogenetic study. *J. Bacteriol.* 173: 697–703.
- Yeaman, M.R. and N.Y. Yount.** 2003. Mechanisms of antimicrobial peptide action and resistance. *Pharmacol. Rev.* 55: 27–55.



This article is published in Open Access model and licensed under a Creative Commons CC BY-NC-ND 4.0, licence available at: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

